The company's R&D expenses grew by $47M, driven by higher employee-related costs.
Filing excerpt
Research and development expenses increased for the year ended June 30, 2026 to $378 million from $331 million for the year ended June 30, 2025, an increase of $47 million or 14%.
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
sec-10kproductLaunchGet every 10-K signal for ResMed and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at ResMed this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/929bbe05-9c0b-4f24-b9eb-4b7290e895d0 returns this record as JSON. POST /v1/companies/enrich returns every signal for resmed.com.
{
"signal_id": "929bbe05-9c0b-4f24-b9eb-4b7290e895d0",
"signal_type": "sec-10k",
"signal_subtype": "productLaunch",
"detected_at": "2026-08-18T07:04:46.423+00:00",
"company": {
"name": "ResMed",
"domain": "resmed.com"
},
"data": {
"detail": "The company's R&D expenses grew by $47M, driven by higher employee-related costs. This investment in innovation suggests a pipeline of new digital health and connected device products, creating opportunities for development, testing, and component vendors.",
"metrics": {
"pct": 0.14,
"timeframe": "current_year",
"pct_context": "Year-over-year increase in R&D expenses",
"dollar_context": "Total R&D expenses for FY2026",
"dollar_millions": 378
},
"summary": "ResMed increases R&D spending by 14% to $378M, signaling focus on new product innovation",
"excerpts": "Research and development expenses increased for the year ended June 30, 2026 to $378 million from $331 million for the year ended June 30, 2025, an increase of $47 million or 14%.",
"relevance": 0.75,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/943819/000094381926000047/rmd-20260630.htm",
"filing_date": "2026-08-13",
"filing_year": 2026,
"fiscal_year_end": "06/30",
"sales_relevance": "Go-to-market support",
"signal_category": "strategic",
"technologies_mentioned": [
"AI",
"cloud-connected devices",
"digital health"
]
}
}
curl https://signals.autobound.ai/v1/signals/929bbe05-9c0b-4f24-b9eb-4b7290e895d0 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"resmed.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.